Pacritinib

CAT: 0013-GTR19171821-02Size: 5 mgDry Ice: NoHazardous: No

1 / 1

CAT#:0013-GTR19171821-02Size:5 mg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

Pacritinib (SB1518) is a potent and selective small molecule inhibitor targeting JAK2 and FLT3 kinases, with cell-free assay IC50 values of 23 nM and 22 nM, respectively. It is widely used in preclinical research for studying myeloproliferative neoplasms and acute myeloid leukemia, demonstrating activity in both cellular assays and in vivo models.

CAS Number

937272-79-2

Product Name Alternative

Inhibitor, Fms like tyrosine kinase 3, FLT3, FLT3 (D835Y), Janus kinase, JAK3, JAK2 (V617F), JAK, JAK2, inhibit, Pacritinib, Cluster of differentiation antigen 135, CD135, SB 1518, SB1518, SB-1518, TyrosineKinases, Tyrosine Kinases, Tyk2

Field of Research

Cardiovascular Research, Epigenetics & Chromatin, Signal Transduction, Stem Cell & Developmental Biology

Purity

≥95% (May vary between batches)

Solubility

H2O:< 1 mg/mL (insoluble or slightly soluble) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.12 mM) ; Ethanol:< 1 mg/mL (insoluble or slightly soluble) ; DMSO:3.57 mg/mL (7.55 mM)

Smiles

C (CN1CCCC1) Oc1ccc2Nc3nccc (n3) -c3cccc (COC\C=C\COCc1c2) c3

Molecular Formula

C28H32N4O3

Molecular Weight

472.58

Storage Conditions

-20°C

Notes

For research use only.

Chemical Information

Pacritinib

Pacritinib is an azamacrocycle with formula C28H32N4O3. It is a Janus kinase inhibitor and its citrate salt is approved for the treatment of intermediate or high risk, primary or secondary myelofibrosis. It has a role as an antineoplastic agent, an anti-inflammatory agent, an apoptosis inducer and an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor. It is a member of benzenes, a cyclic ether, a member of pyrrolidines and an azamacrocycle. It is a conjugate base of a pacritinib(1+).

CAS Number	937272-79-2
PubChem CID	46216796
IUPAC Name	(16E)-11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(24),2(27),3,5,8(26),9,11,16,21(25),22-decaene
Molecular Formula	C28H32N4O3
Molecular Weight	472.6
XLogP	3.8
Topological Polar Surface Area	68.7
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	4
Heavy Atom Count	35
Formal Charge	0
Complexity	644

SMILES

C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2

InChI

InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+

InChIKey

HWXVIOGONBBTBY-ONEGZZNKSA-N

Chemical Structure

2D Structure

CAS: 937272-79-2

CID: 46216796

Formula: C28H32N4O3

MW: 472.6

Interactive 3D Structure

Loading 3D structure...

View on PubChem Raw 3D data

Computed Properties

Property	Value
Molecular Weight	472.6
XLogP3	3.8
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	4
Exact Mass	472.24744090
Monoisotopic Mass	472.24744090
Topological Polar Surface Area	68.7 Å²
Heavy Atom Count	35
Formal Charge	0
Complexity	644
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	1
Undefined Bond Stereocenter Count	0
Covalently-Bonded Unit Count	1
Compound Is Canonicalized	Yes

Alternative Products

Catalog	Name
HY-16379-01	Pacritinib
HY-16379B-01	Pacritinib (citrate)
HY-16379R-01	Pacritinib (Standard)
202571	Pacritinib (SB1518)
MBS5806943	Pacritinib hydrochloride
CS-O-59407	Pacritinib-d8
B2485-1	EZSolution™ Pacritinib
2450-5	SB1518 (Pacritinib)

Pacritinib

Chemical Information

Alternative Products

Popular Products